Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Double-blind, Placebo-controlled, Randomized, Single- And Multiple-ascending Dose Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Pf-06293620 In Subjects With Type 2 Diabetes Mellitus

NCT02211261 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02211261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02211261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Double-blind, Placebo-controlled, Randomized, Single- And Multiple-ascending Dose Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Pf-06293620 In Subjects With Type 2 Diabetes Mellitus
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
September 15, 2014
Completion date
January 27, 2017
Enrollment
84 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus